ANXA5 and myelodysplastic syndrome: Co-treatment with lenalidomide and Cyclosporin-A also correlates with more Annexin V+ cells than single treatment with lenalidomide in primary bone marrow cells from MDS patients who are diagnosed with del(5q) MDS or RAEB II.